Evidence-based treatments for human health
We are building a pipeline of evidence-based health products, through in-house development and in-licensing / partnership opportunities.
Obesity is a medical condition of such prevalence that it is described as a new pandemic. With associated significant comorbidities and health risk factors, Anatara Lifesciences is excited to announce that it is commencing a new anti-obesity project.
The project aims to develop an oral medication to assist weight reduction and sustain weight control in conjunction with other contemporary treatments and approaches.
Anatara Lifesciences has now concluded its human clinical trial on Irritable Bowel Syndrome (IBS).
Anatara Lifesciences (ASX:ANR) specialises in creating evidence-based innovative products to address unmet needs in human health. Our focus is on building a pipeline of health products through development of our own proprietary technology as well as strategic partnerships. Our core commitment is to deliver tangible benefits to patients and create significant value for our shareholders.
Irritable Bowel Syndrome (IBS) is the most commonly diagnosed gastrointestinal condition and a significant cost burden on health care.
Anatara Lifesciences is developing and commercialising innovative, evidence-based health products to address significant unmet need, with a particular focus on conditions that involve the complexity of the gastrointestinal tract